ATE296538T1 - Rotavirus impfstoffformulierungen - Google Patents

Rotavirus impfstoffformulierungen

Info

Publication number
ATE296538T1
ATE296538T1 AT00955357T AT00955357T ATE296538T1 AT E296538 T1 ATE296538 T1 AT E296538T1 AT 00955357 T AT00955357 T AT 00955357T AT 00955357 T AT00955357 T AT 00955357T AT E296538 T1 ATE296538 T1 AT E296538T1
Authority
AT
Austria
Prior art keywords
formulations
vaccine formulations
rotavirus vaccine
rotavirus
vaccines
Prior art date
Application number
AT00955357T
Other languages
English (en)
Inventor
Carl J Burke
David B Volkin
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE296538T1 publication Critical patent/ATE296538T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AT00955357T 1999-08-03 2000-08-03 Rotavirus impfstoffformulierungen ATE296538T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/366,616 US6403098B1 (en) 1996-09-26 1999-08-03 Rotavirus vaccine formulations
PCT/US2000/021264 WO2001008495A1 (en) 1999-08-03 2000-08-03 Rotavirus vaccine formulations

Publications (1)

Publication Number Publication Date
ATE296538T1 true ATE296538T1 (de) 2005-06-15

Family

ID=23443770

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00955357T ATE296538T1 (de) 1999-08-03 2000-08-03 Rotavirus impfstoffformulierungen

Country Status (11)

Country Link
US (1) US6403098B1 (de)
EP (1) EP1206189B1 (de)
JP (1) JP4138314B2 (de)
AT (1) ATE296538T1 (de)
AU (1) AU6757600A (de)
CA (1) CA2378864A1 (de)
DE (1) DE60020570T2 (de)
DK (1) DK1206189T3 (de)
ES (1) ES2240145T3 (de)
PT (1) PT1206189E (de)
WO (1) WO2001008495A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6616931B1 (en) * 1996-09-26 2003-09-09 Merck & Co., Inc. Rotavirus vaccine formulations
DE122006000026I1 (de) * 1999-08-17 2006-10-12 Glaxosmithkline Biolog Sa Methoden um Rotavirusvarianten zu trennen und lebender attenuierter Rotavirus impfstoff
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
EP1327450B1 (de) * 2002-01-15 2007-08-15 Bio Life Science Forschungs- und Entwicklungsges.m.b.H. Orale Vakzinierung mit nackten Tumor-Antigen-Mimotopen
ATE361097T1 (de) * 2002-01-15 2007-05-15 Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh Orale vakzinierung mit dem tumor-antigen-mimotop gln-met-trp-ala-pro-gln-trp-gly-pro-asp
WO2005099751A2 (en) 2004-04-01 2005-10-27 Alza Corporation Apparatus and method for transdermal delivery of influenza vaccine
GB0503337D0 (en) * 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
WO2007081447A2 (en) 2005-11-22 2007-07-19 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US20100056825A1 (en) * 2008-08-28 2010-03-04 Telik, Inc. Formulations of canfosfamide and their preparation
US8324426B2 (en) * 2008-08-28 2012-12-04 Telik, Inc. Formulations of canfosfamide and their preparation
CN102202688B (zh) * 2008-11-07 2017-04-12 印度血清研究所私人有限公司 稳定、干燥的轮状病毒疫苗、其组合物和制备其的方法
WO2012075379A2 (en) 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Liquid viral formulations
AU2011336410B2 (en) 2010-12-02 2015-01-22 Oncolytics Biotech Inc. Lyophilized viral formulations
JP5798356B2 (ja) * 2011-04-06 2015-10-21 一般財団法人化学及血清療法研究所 新規インフルエンザワクチン安定化剤
HUE035774T2 (en) 2011-08-12 2018-05-28 Merial Inc Biological substances, in particular vaccines, preserved by vacuum
WO2013029033A2 (en) * 2011-08-25 2013-02-28 Brian Pulliam Rotavirus preparations with excess calcium ions and high viscosities that ensure vaccine viability at elevated temperatures
CN110227152A (zh) 2012-04-23 2019-09-13 巴拉特生物技术国际有限公司 轮状病毒疫苗组合物及其制备方法
US9480739B2 (en) * 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
US10532093B2 (en) * 2014-07-18 2020-01-14 Mds Wellcome Trust Hilleman Laboratories Pvt. Ltd. Thermostable freeze dried rotavirus vaccine formulation and process to prepare thereof
US10556000B2 (en) * 2014-07-18 2020-02-11 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Thermostable spray dried rotavirus vaccine formulation and process thereof
MA44557B1 (fr) 2016-06-16 2021-11-30 Bharat Biotech Int Ltd Vaccin contre le rotavirus sans tampon, stable en milieu acide, et d'un faible volume de dose à administrer
PL3522871T3 (pl) * 2016-10-05 2022-02-14 Zoetis Services Llc Sposoby liofilizacji, które zapewniają stabilne odwodnione pierwotniaki do zastosowania jako silne żywe szczepionki
US11110163B2 (en) 2017-02-14 2021-09-07 Inventprise, Llc Heat stable vaccines
US10413604B2 (en) 2017-02-14 2019-09-17 Inventprise, Llc Heat stable liquid rotavirus vaccine
CN111150849A (zh) * 2020-04-02 2020-05-15 广州隽沐生物科技股份有限公司 一种组合物及其制备方法及其应用
CN114392237B (zh) * 2021-12-28 2024-02-02 上海允英生物医药科技有限公司 一种冻干病毒制剂及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT71926B (en) * 1979-10-29 1982-03-31 Merck & Co Inc Process for preparing a liquid vaccine comprising a stabilizer
FR2505657A1 (fr) * 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
US4636385A (en) 1985-02-15 1987-01-13 The Wistar Institute Of Anatomy & Biology Vaccine, method for its preparation, and use thereof in vaccinating humans against rotavirus infection
US5626851A (en) 1987-11-30 1997-05-06 The Wistar Institute Of Anatomy And Biology Rotavirus reassortant vaccine
WO1996001651A1 (en) 1994-07-11 1996-01-25 The Government Of The United States Of America, Represented By The Department Of Health And Human Services Attenuated human rotavirus vaccine
EP1181937A3 (de) * 1994-08-09 2004-02-04 Cytrx Corporation Nukleinsäure enthaltender Impfstoff, Impfstoff-adjuvans
US5827534A (en) 1995-05-24 1998-10-27 University Of Maryland At Baltimore Oral dosage composition comprising zonnula occludens toxin and a therapeutic agent for intestinal delivery
ES2294801T3 (es) * 1996-09-26 2008-04-01 MERCK & CO., INC. Formulaciones de vacunas contra rotavirus.
US6210683B1 (en) * 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines

Also Published As

Publication number Publication date
WO2001008495A1 (en) 2001-02-08
EP1206189A4 (de) 2003-03-12
JP4138314B2 (ja) 2008-08-27
US6403098B1 (en) 2002-06-11
AU6757600A (en) 2001-02-19
ES2240145T3 (es) 2005-10-16
DK1206189T3 (da) 2005-08-29
DE60020570T2 (de) 2006-05-04
JP2003505482A (ja) 2003-02-12
EP1206189B1 (de) 2005-06-01
PT1206189E (pt) 2005-09-30
DE60020570D1 (de) 2005-07-07
EP1206189A1 (de) 2002-05-22
CA2378864A1 (en) 2001-02-08

Similar Documents

Publication Publication Date Title
DK1206189T3 (da) Rotavirusvaccineformuleringer
MY129263A (en) Vaccine composition
HUP0101619A2 (hu) Adjuvánskészítmények
PT1412384E (pt) Formulação estável de glp-1 modificado
DE60038183D1 (de) Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe
SE8804629D0 (sv) New therapeutically active compounds
DK1299348T3 (da) Forbindelser og sammensætninger til levering af aktive midler
FR2762843B1 (fr) Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
EE05089B1 (et) Amiidasendatud imidasokinoliinid ja neid sisaldavad farmatseutilised preparaadid
MXPA03005464A (es) Agentes antivirales.
MXPA02006029A (es) Lipopeptidos novedosos como agentes antibacterianos.
DK1187629T3 (da) Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
HK1076605A1 (en) Formulations
MXPA02006030A (es) Lipopeptidos como agentes antibacterianos.
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
HUP0301349A2 (hu) IL-11-tartalmú készítmények
MXPA03007857A (es) Compuestos y composiciones para entregar agentes activos.
AU2002221519A1 (en) Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
DK1057828T3 (da) Orale trovafloxacin-suspensioner
EE200200252A (et) Antikehade kasutamine vaktsiinidena, antikehi sisaldavad farmatseutilised kompositsioonid, meetod antikehapreparaadi valmistamiseks ja meetod farmatseutilise kompositsiooni valmistamiseks
AP9801235A0 (en) Erythromycin derivatives.
YU24603A (sh) Novi farmaceutski preparati koji sadrže epinastin i pseudoefedrin
FR2809961B1 (fr) Utilisation d'ethers de sucres, comme adjuvants d'immunite dans les compositions vaccinales, compositions therapeutiques les renfermant et leur utilisation comme vaccins
IL150979A0 (en) 9-alkylamino-1-nitroacridine derivatives
IT1317836B1 (it) Uso del tiamfenicolo per la preparazione di composizioni farmaceuticheutili per il trattamento di infezioni da staphylococci

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1206189

Country of ref document: EP

EEFA Change of the company name